[HTML][HTML] Nintedanib in progressive fibrosing interstitial lung diseases

…, AU Wells, V Cottin, A Devaraj… - … England Journal of …, 2019 - Mass Medical Soc
Background Preclinical data have suggested that nintedanib, an intracellular inhibitor of
tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the …

Interstitial lung disease in systemic sclerosis: a simple staging system

…, TJ Corte, CR Sander, J Ratoff, A Devaraj… - American journal of …, 2008 - atsjournals.org
Rationale: In interstitial lung disease complicating systemic sclerosis (SSc-ILD), the optimal
prognostic use of baseline pulmonary function tests (PFTs) and high-resolution computed …

Respiratory follow-up of patients with COVID-19 pneumonia

…, SL Barratt, R Condliffe, SR Desai, A Devaraj… - Thorax, 2020 - thorax.bmj.com
The COVID-19 pandemic has led to an unprecedented surge in hospitalised patients with
viral pneumonia. The most severely affected patients are older men, individuals of black and …

European position statement on lung cancer screening

M Oudkerk, A Devaraj, R Vliegenthart… - The Lancet …, 2017 - thelancet.com
Lung cancer screening with low-dose CT can save lives. This European Union (EU) position
statement presents the available evidence and the major issues that need to be addressed …

Pulmonary angiopathy in severe COVID-19: physiologic, imaging, and hematologic observations

…, SJ Wort, T Xu, SPG Padley, A Devaraj… - American journal of …, 2020 - atsjournals.org
Rationale: Clinical and epidemiologic data in coronavirus disease (COVID-19) have accrued
rapidly since the outbreak, but few address the underlying pathophysiology. Objectives: To …

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised …

…, KR Flaherty, KK Brown, Y Inoue, A Devaraj… - The lancet Respiratory …, 2020 - thelancet.com
Background The INBUILD trial investigated the efficacy and safety of nintedanib versus
placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than …

[PDF][PDF] Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease

…, P Ghai, K Suveizdyte, RJ Hewitt, SR Desai, A Devaraj… - Immunity, 2022 - cell.com
Some patients hospitalized with acute COVID-19 suffer respiratory symptoms that persist for
many months. We delineated the immune-proteomic landscape in the airways and …

CT lung abnormalities after COVID-19 at 3 months and 1 year after hospital discharge

B Vijayakumar, J Tonkin, A Devaraj, KEJ Philip… - Radiology, 2022 - pubs.rsna.org
Background Data on the long-term pulmonary sequelae in COVID-19 are lacking. Purpose
To assess symptoms, functional impairment, and residual pulmonary abnormalities on serial …

[HTML][HTML] The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer.

…, DR Baldwin, KE Brain, A Devaraj… - Health technology …, 2016 - ncbi.nlm.nih.gov
BACKGROUND Lung cancer kills more people than any other cancer in the UK (5-year
survival< 13%). Early diagnosis can save lives. The USA-based National Lung Cancer …

Detection of pulmonary hypertension with multidetector CT and echocardiography alone and in combination

A Devaraj, AU Wells, MG Meister, TJ Corte, SJ Wort… - Radiology, 2010 - pubs.rsna.org
Purpose To test the reliability of potentially new computed tomographic (CT) indicators of
pulmonary hypertension (PH) and to establish whether a combination of CT and …